Related Experiment Videos
Validation of the Composite Laryngeal Recurrence Staging System
Peter D Lacy1, John T Kennedy, Jay F Piccirillo
1Department of Otolaryngology, Royal Victorian Eye and Ear Hospital, Melbourne, Australia. entdoc@iol.ie
Cancer
|August 12, 2004
Summary
The Composite Laryngeal Recurrence Staging System (CLRSS) effectively stages more recurrent laryngeal cancer patients than the rTNM system. CLRSS also offers superior survival prediction for laryngeal cancer recurrence.
Area of Science:
- Oncology
- Head and Neck Surgery
- Cancer Staging
Background:
- Recurrent laryngeal squamous cell carcinoma presents a challenge for accurate staging.
- The Composite Laryngeal Recurrence Staging System (CLRSS) has emerged as a potential improvement over the retreatment TNM (rTNM) system.
Purpose of the Study:
- To validate the CLRSS for staging recurrent laryngeal carcinoma.
- To compare the staging and survival prediction capabilities of CLRSS against the rTNM system.
Main Methods:
- Retrospective chart review of 67 patients with recurrent laryngeal squamous cell carcinoma treated between 1980 and 1992.
- Assessment of CLRSS external validity and comparison of its staging and survival prediction with rTNM.
Main Results:
- The CLRSS successfully staged all 67 patients, unlike the rTNM system which failed to stage 18% (12 patients).
- CLRSS demonstrated superior survival prediction compared to rTNM, with a c-statistic of 0.79.
- The overall 2-year survival rate for the cohort was 51%.
Conclusions:
- The CLRSS is a more effective staging system for recurrent laryngeal carcinoma.
- CLRSS outperforms rTNM in its capacity to stage patients and predict survival outcomes.